According to a new report, published by KBV research, The Global Newborn Screening Market size is expected to reach $1.6 billion by 2028, rising at a market growth of 6.4% CAGR during the forecast period.
The Instrument market would experience a CAGR of 7.7% during (2022 - 2028). It is because all of the instruments and reagents are required to execute a comprehensive and pocket-friendly newborn screening test. Newborn Screening instruments, such as Modular and Fully Automated newborn screening Instrumentation, manual and automated equipment, and reagent kits, are available in the market.
The Blood Test market is leading the Global Newborn Screening Market by Test Type in 2021, achieving a market value of $701 Million by 2028. Most newborn screenings use a blood test to detect rare but critical health conditions. To obtain, a few drops of blood, a health care worker pricks baby's heel. A doctor collects the blood on parchment and sends it to the laboratory for analysis. child's blood test results are usually ready by the time baby is five to seven days old.
The Clinical Laboratories market has high growth rate of 7.9% during (2022 - 2028). Clinical laboratories are medical facilities that use a variety of laboratory procedures to help doctors diagnose, treat, and manage patients. Clinical laboratory scientists work in these labs and are educated to perform numerous tests on samples of biological specimens gathered from patients. To provide access to both patients and medical professionals, the majority of clinical laboratories are located within or near hospital facilities.
The Tandem Mass Spectrometry (TMS) market shows high market share in the Global Newborn Screening Market by Technology in 2021, achieving a market value of $416.8 Million by 2028. It is due to the Rapid molecular assays, Reverse transcription-polymerase Chain Reaction (RT-PCR), and other nucleic acid amplification tests are among the molecular assays available for identifying influenza virus infection. These tests have a high sensitivity and specificity for detecting influenza virus RNA or nucleic acids in respiratory material.
The North America market region shows high market share in the Global Newborn Screening Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $578.8 Million by 2028. The Europe market would exhibit a CAGR of 6.2% during (2022 - 2028). Additionally, The Asia Pacific market is poised to grow at a CAGR of 7.2% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/newborn-screening-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of General Electric (GE) Co. (GE Healthcare), F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Natus Medical Incorporated, Masimo Corporation, Waters Corporation, PerkinElmer, Inc., AB Sciex LLC (Danaher Corporation), Medtronic PLC (Covidien plc), Trivitron Healthcare Pvt. Ltd.
By Product Type
By Test Type
By End User
By Technology
By Geography
Companies Profiled
Unique Offerings 
